Your browser doesn't support javascript.
loading
Safety, Pharmacokinetic, and Pharmacodynamic Study of a Sublingual Formula for the Treatment of Vasovagal Syncope.
Hutson, Paul; Guieu, Regis; Deharo, Jean-Claude; Michelet, Pierre; Brignole, Michele; Vander Ark, Cassondra; Hamdan, Mohamed H.
Afiliação
  • Hutson P; School of Pharmacy, University of Wisconsin-Madison, 777 Highland Avenue, Madison, WI, 53705, USA. paul.hutson@wisc.edu.
  • Guieu R; Assistance Publique, Hôpitaux de Marseille, Centre Hospitalier Universitaire La Timone, Service de Cardiologie, Marseille, France.
  • Deharo JC; Aix Marseille Université, C2VN, Marseille, France.
  • Michelet P; Assistance Publique, Hôpitaux de Marseille, Centre Hospitalier Universitaire La Timone, Service de Cardiologie, Marseille, France.
  • Brignole M; Aix Marseille Université, C2VN, Marseille, France.
  • Vander Ark C; Assistance Publique, Hôpitaux de Marseille, Centre Hospitalier Universitaire La Timone, Service de Cardiologie, Marseille, France.
  • Hamdan MH; Aix Marseille Université, C2VN, Marseille, France.
Drugs R D ; 22(1): 61-70, 2022 Mar.
Article em En | MEDLINE | ID: mdl-35150431
ABSTRACT

BACKGROUND:

Vasovagal syncope is a common cause of syncope which, if recurrent, can have multiple negative consequences such as injury and occupational disability. Various medications can be used to decrease the recurrence of vasovagal syncope but there are no drugs that can be used by patients to interrupt a perceived vasovagal episode.

METHODS:

A phase I study was performed to evaluate the tolerability and safety of a gel formulation containing capsaicin (1 mg), phenylephrine HCL (PE) and caffeine citrate (200 mg) (CPC) in normal adult volunteers. Secondary objectives were to characterize the pharmacokinetics (PK) of the CPC formulation and the highest dose of PE needed to achieve a target increase in systolic BP of at least 40 mmHg. After receiving the first dose, a second dose of the CPC mixture was administered at 2 h. Suboptimal changes in systolic blood pressure (SBP) were noted at PE doses of 0.6, 1.2, and 1.8 mg, therefore a second cohort was studied at PE doses of 10, 20, and 30 mg. Blood samples were collected in rapid sequence and were assayed for all three drugs.

RESULTS:

A total of 17 subjects received the drug with no serious adverse effects reported. All doses were well tolerated, although the capsaicin content usually caused expected temporary oral and gastric discomfort. One subject did not complete the study because of a vasovagal reaction that was associated with the frequent blood sampling. There was a 5-25 min lag in the appearance of measurable blood concentrations of capsaicin and phenylephrine. Most subjects had baseline caffeine concentrations from dietary use, with a gradual increase noted after 15 min consistent with GI absorption. Although the intended criterion of a 40 mmHg increase in SBP was not reached, a clinically significant increase in BP for at least 15 min was noted in the six subjects who received the highest dose of PE (30 mg), with a gradual decline over the next 2 h.

CONCLUSION:

The ternary mixture of capsaicin, phenylephrine, and caffeine was well tolerated when administered as two sublingual/oral doses over a 2-h period.
Assuntos

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Assunto principal: Síncope Vasovagal Limite: Adult / Humans Idioma: En Revista: Drugs R D Assunto da revista: TERAPIA POR MEDICAMENTOS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Assunto principal: Síncope Vasovagal Limite: Adult / Humans Idioma: En Revista: Drugs R D Assunto da revista: TERAPIA POR MEDICAMENTOS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos